T Cell Link Confirmed in RA Lung Disease
Posted on: Friday, 7 January 2005, 21:00 CST
Researchers at the Mayo Clinic in Minnesota have discovered overly abundant T cells in sufferers of rheumatoid arthritis lung disease.
Researchers at the Rochester clinic found that specific T cells of the immune system were more abundant in tissue samples from patients with RA lung disease than in tissue samples from patients who have other forms of lung disease.
These cells, CD4 and CD3 cells, normally would protect the body against disease. Their abundance in patients' lungs, however, suggests therapies specifically directed against T cells and T cell function could succeed where earlier therapeutic approaches did not.
Our work provides the evidence that was lacking, so from that standpoint it is a very helpful demonstration that hopefully will lead to the development of new treatment strategies for RA lung disease, said Dr. Carl Turesson, former Mayo Clinic research fellow now working at Malmo University Hospital in Sweden.
The researchers also found that computer-assisted image analysis aided in the detection of RA lung disease, allowing earlier diagnosis and treatment.
The research appears in Friday's online version of the Jan. 13 edition of Arthritis & Rheumatism.
Source: United Press International
Related Articles
- Boehringer Ingelheim to Commence Phase III Study Investigating the Role of BIBW 2992 as First-Line Treatment for Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR Mutations
- Data From Studies of Amrubicin in Small-Cell Lung Cancer Presented at the 2008 American Society of Clinical Oncology Meeting Demonstrate Single Agent Anti-Tumor Activity in Western Patient Population
- Study Showed ALIMTA(R) (Pemetrexed for Injection) Improved Survival in Certain Types of Non-Small Cell Lung Cancer
- GlobeImmune Announces Initiation of a Phase 2a Clinical Trial of GI-4000 in Patients With Non-Small Cell Lung Cancer at Memorial Sloan Kettering
- Introgen Announces Positive Phase 2 Clinical Trial Results With INGN 225 Immunotherapy in Patients With Small Cell Lung Cancer
- Sunesis Pharmaceuticals Reports Positive Initial Results From Phase 2 Small Cell Lung Cancer Trial With SNS-595
- Poniard Pharmaceuticals Completes Enrollment in Picoplatin Phase 2 Small Cell Lung Cancer Clinical Trial
- NeoRx Announces Treatment of First Patient With Picoplatin in Phase 2 Clinical Trial in Small Cell Lung Cancer
- STELLAR 3 Pivotal Trial Shows XYOTAX(TM) Reduces Side Effects of Paclitaxel With Equivalent Efficacy in the Treatment of Non-Small Cell Lung Cancer (NSCLC) Patients
- A Pragmatic and Successful Approach to Treating Nonsmall-Cell Lung Carcinoma
 |
 |
User Comments (0)
RSS Feeds